Adjuvant Capecitabine vs Gemcitabine Plus Cisplatin in Resected Extrahepatic Cholangiocarcinoma

PHASE2CompletedINTERVENTIONAL
Enrollment

101

Participants

Timeline

Start Date

May 15, 2017

Primary Completion Date

December 15, 2021

Study Completion Date

November 15, 2022

Conditions
CholangiocarcinomaBiliary Tract CancerAdjuvant ChemotherapyCapecitabineGemcitabineCisplatin
Interventions
DRUG

Gemcitabine plus cisplatin

Gemcitabine 1,000 mg/m2 and cisplatin 25 mg/m2 Day 1 and 8, every 3 weeks

DRUG

Capecitabine

Capecitabine 1,250 mg/m2 Day 1 to 14, every 3 weeks

Trial Locations (1)

05505

Asan Medical Center, University of Ulsan College of Medicine, Seoul

Sponsors
All Listed Sponsors
collaborator

Bundang CHA Hospital

OTHER

collaborator

Seoul St. Mary's Hospital

OTHER

collaborator

Severance Hospital

OTHER

lead

Asan Medical Center

OTHER

NCT03079427 - Adjuvant Capecitabine vs Gemcitabine Plus Cisplatin in Resected Extrahepatic Cholangiocarcinoma | Biotech Hunter | Biotech Hunter